ESC 365 - ENTRIGUE: Pegozafermin for the treatment of severe hypertriglyceridemia.

ESC Professional Premium Access

ENTRIGUE: Pegozafermin for the treatment of severe hypertriglyceridemia.

Session: Late-Breaking Science - Innovations in drug treatment

Topic: Drug therapy

Speaker: Professor D. Bhatt (New York, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York (United States of America)

49 presentations

11 followers

3 more presentations in this session

Mechanisms of the clinical benefits of SGLT2i in heart failure (EMPEROR-Pooled)

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Lifetime prediction and Treatment Benefit in HFrEF (LIFE-HF).

Speaker: Doctor S. Koudstaal (Gouda, NL)

Genotype-Guided Oral P2Y12 Inhibitor Therapy Reduces Cumulative Ischemic Events Following Percutaneous Coronary Intervention - A Prespecified Secondary Analysis of the TAILOR-PCI Randomised Trial

Speaker: Doctor B. Ingraham (Rochester, US)

Access the full session

Late-Breaking Science - Innovations in drug treatment

Speakers: Professor D. Bhatt, Professor F. Zannad, Doctor S. Koudstaal, Doctor B. Ingraham

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources